U.S. Pharmaceuticals & Biotech Buy the Dip

Celcuity

Market Cap: US$4.3b

A clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States.

Tango Therapeutics

Market Cap: US$4.0b

A precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.

NewAmsterdam Pharma

Market Cap: US$3.6b

A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease.

Vera Therapeutics

Market Cap: US$2.8b

A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.

Celldex Therapeutics

Market Cap: US$2.8b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

COMPASS Pathways

Market Cap: US$1.7b

Operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States.

AnaptysBio

Market Cap: US$1.6b

A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.

Capricor Therapeutics

Market Cap: US$1.1b

A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.

Solid Biosciences

Market Cap: US$891.0m

Develops therapies for neuromuscular and cardiac diseases in the United States.

Phathom Pharmaceuticals

Market Cap: US$871.3m

A biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States.

Design Therapeutics

Market Cap: US$787.6m

A clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States.

Ironwood Pharmaceuticals

Market Cap: US$637.1m

A biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.

Allogene Therapeutics

Market Cap: US$617.8m

A clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.

4D Molecular Therapeutics

Market Cap: US$566.7m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Kyverna Therapeutics

Market Cap: US$452.3m

A late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases.

Prelude Therapeutics

Market Cap: US$414.6m

A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

Sutro Biopharma

Market Cap: US$393.2m

Operates as an oncology company.

Lyell Immunopharma

Market Cap: US$324.1m

A clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.

Fate Therapeutics

Market Cap: US$318.2m

A clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally.

Opus Genetics

Market Cap: US$270.8m

A clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.

Precision BioSciences

Market Cap: US$214.7m

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

Coherus Oncology

Market Cap: US$214.4m

A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.

Karyopharm Therapeutics

Market Cap: US$212.6m

A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

Nkarta

Market Cap: US$186.0m

A clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.

Acumen Pharmaceuticals

Market Cap: US$156.7m

A clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease.

Pyxis Oncology

Market Cap: US$141.3m

A clinical stage company, engages in the development of therapeutics to treat solid tumors.

Spruce Biosciences

Market Cap: US$121.9m

A biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Burning Rock Biotech

Market Cap: US$101.3m

Develops and sells cancer therapy selection tests in the People's Republic of China and the United States.

Cognition Therapeutics

Market Cap: US$84.1m

A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

LeonaBio

Market Cap: US$73.4m

LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis.

Talphera

Market Cap: US$70.1m

A specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.

iBio

Market Cap: US$67.1m

A preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space.

Polyrizon

Market Cap: US$24.3m

A biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.

Universe Pharmaceuticals

Market Cap: US$3.0m

Through its subsidiaries, engages in the manufacturing, marketing, distribution, and sales of traditional Chinese medicine derivative products in China.